ABSTRACT

Introduction: Abdominal aortic aneurysm (AAA) is a common, complex, and life-threatening disease. Currently, the pathogenesis of AAA is not well understood. No biomarkers or specific drugs are available for AAA in clinical applications. Proteomics is a powerful tool in biomarker discovery, exploration of pathogenesis, and drug target identification.

Areas covered: We review the application of mass spectrometry-based proteome analysis in AAA patients within the last ten years. Differentially expressed proteins associated with AAA were identified in multiple sample sources, including vascular tissue, intraluminal thrombus, tissue secretome, blood, and cells. Some potential disease biomarkers, pathogenic mechanisms, or therapeutic targets for AAA were discovered using proteome analysis. The challenges and prospects of proteomics applied to AAA are also discussed.

Expert opinion: Since most of the previous proteomic studies used relatively small sample sizes, some promising biomarkers need to be validated in multicenter cohorts to accelerate their clinical application. With the rapid development of mass spectrometry technology, modification-specific proteomics and multi-omics research in the future will enhance our understanding of the pathogenesis of AAA and promote biomarker discovery and drug development for clinical translation.

摘要

简介：腹主动脉瘤（AAA）是一种常见、复杂且危及生命的疾病。目前，AAA的发病机制尚不清楚。在临床应用中没有可用于 AAA 的生物标志物或特定药物。蛋白质组学是生物标志物发现、发病机制探索和药物靶点鉴定的有力工具。

涵盖的领域：我们回顾了过去十年中基于质谱的蛋白质组分析在 AAA 患者中的应用。在多个样品来源中鉴定出与 AAA 相关的差异表达蛋白，包括血管组织、管腔内血栓、组织分泌物、血液和细胞。使用蛋白质组分析发现了 AAA 的一些潜在疾病生物标志物、致病机制或治疗靶点。还讨论了应用于 AAA 的蛋白质组学的挑战和前景。

专家意见：由于之前的大多数蛋白质组学研究都使用了相对较小的样本量，一些有前景的生物标志物需要在多中心队列中进行验证，以加速其临床应用。随着质谱技术的快速发展，未来修饰特异性蛋白质组学和多组学研究将加深我们对AAA发病机制的认识，促进生物标志物发现和临床转化药物开发。